Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Continuous chromatographic separation technology of gentamycin C1a

A continuous chromatography and gentamicin technology, which is applied in the field of separation and purification of high-purity gentamicin C1a recovered liquid, can solve problems such as difficult removal, achieve high resin utilization, compact system, and reduce labor load

Active Publication Date: 2016-04-27
WUXI JIMIN KEXIN SHANHE PHARMA +1
View PDF6 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is a large part of impurities in the recovery solution of gentamicin C1a, such as 1-N-ethyl galosamine, 6″-N-ethyl gentamicin C1a, 1-N-ethyl gentamicin These impurities are similar in structure to gentamicin C1a, and are difficult to remove with traditional fixed beds. Therefore, it is necessary to develop efficient separation and purification processes to improve product quality and promote green chemistry.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Continuous chromatographic separation technology of gentamycin C1a
  • Continuous chromatographic separation technology of gentamycin C1a

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Combine below figure 1 And the embodiment is described in detail:

[0046] The selected resin of the present invention is No. 1 resin of Huazhen chromatography, and the resin particle diameter is more than 95% of 100 orders, and the filling capacity of each resin column is 0.08m 3 , the capacity of the resin column is 0.1m 3 , the actual filling ratio is 80%. The total size of the system is 3m×3m×5m (length×width×height).

[0047] The disc transfer type continuous chromatographic separation system separates gentamicin C1a into the following areas:

[0048] 1) Adsorption area: (Unit 11)

[0049] There is 1 unit (unit 11) in this area. Through flow rate control, the raw material first enters unit 11, and then enters unit 12 through series connection for cleaning.

[0050] 2) Laundry area: (Units 10, 12-14)

[0051]After adsorption, each resin needs to be washed with water, located before and after the adsorption zone. After the resin column rotates to the adsorptio...

Embodiment 2

[0066] Combine below figure 1 And the embodiment is described in detail:

[0067] The selected resin of the present invention is YPR-II resin, and the resin is 80 mesh, and the filling capacity of each resin column is 0.08m 3 , the capacity of the resin column is 0.1m 3 , the actual filling ratio is 80%. The total size of the system is about 3m×3m×5m (length×width×height).

[0068] The simulated moving bed continuous chromatographic separation system separates gentamicin C1a into the following areas:

[0069] 1) Adsorption area: (Unit 11)

[0070] There is 1 unit (unit 11) in this area. Through flow rate control, the raw material first enters unit 11, and then enters unit 12 through series connection for cleaning.

[0071] 2) Laundry area: (Units 10, 12-14)

[0072] After adsorption, each resin needs to be washed with water, located before and after the adsorption zone. After the resin column rotates to the adsorption water washing area, the material liquid (mainly clar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a continuous separation and purification technology of gentamycin C1a. Efficient separation of a gentamycin C1a recovered liquid is realized through using a continuous chromatographic separation technology. The technology comprises the following steps: allowing recovered gentamycin C1a to enter a continuous chromatographic system, adsorbing, washing out impurities, eluting, collecting the obtained eluate, regenerating a chromatographic column, and concentrating the collected eluate to obtain gentamycin C1a. The gentamycin C1a separated in through the technology has the advantages of high yield and high purity, so the technology has the advantages of low cost, environmental protection and suitableness for industrial production.

Description

technical field [0001] The invention belongs to the field of semi-synthetic chemical pharmacy and relates to a method for separating and purifying high-purity gentamycin C1a recovered liquid. Background technique [0002] Etimicinsulfate (Etimicinsulfate) is a new generation of semi-synthetic aminoglycoside antibiotics with high efficiency, low toxicity and resistance to drug-resistant bacteria with independent intellectual property rights. It is the only antibiotic that has obtained the national first-class new drug certificate. Infectious medicines. This product is suitable for sensitive Escherichia coli, Klebsiella pneumoniae, Serratia spp., A. citrate, Enterobacter spp., Acinetobacter spp., Proteus spp., Haemophilus influenzae, aeruginosa Various infections caused by Pseudomonas and Staphylococci etc. Clinical studies have shown that this product has a good effect on the following infections: Respiratory tract infections: such as acute bronchitis, acute exacerbation of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H15/236C07H1/06
CPCY02P20/582C07H15/236C07H1/06
Inventor 薛超一
Owner WUXI JIMIN KEXIN SHANHE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com